Allscripts Healthcare Stock
Your prediction
Pros and Cons of Allscripts Healthcare in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allscripts Healthcare vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allscripts Healthcare | - | 17.647% | 11.111% | -42.857% | 11.111% | -74.359% | -71.014% |
| Simulations Plus | -4.110% | -19.540% | -9.091% | -62.162% | -9.091% | -62.162% | -78.125% |
| MicroVision Inc | -3.380% | -6.622% | -11.787% | -56.165% | -10.371% | -78.211% | -89.427% |
| Fonar Corp. New | 0.000% | -0.641% | -1.274% | 1.974% | -0.641% | -4.321% | 3.333% |
Comments
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at TD Cowen from $26.00 to $15.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at Royal Bank of Canada from $22.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat